<ul>
<li><strong>基于患者测序数据设计的专有 AI-Immunology™平台，EVX-04 靶向多种非传统内源性逆转录病毒（ERV）肿瘤抗原</strong></li>
<li><strong>EVX-04 在临床前模型中诱导靶向免疫反应并防止肿瘤生长</strong></li>
<li><strong>EVX-04 是一种现成的治疗性癌症疫苗，专为急性髓性白血病（AML）开发，该疾病以高死亡率和巨大的未满足医疗需求为特征</strong></li>
<li><strong>EVX-04 背后的现成疫苗概念</strong> <strong>在其他难治性癌症中具有广泛的潜在应用</strong></li>
</ul>
<p>丹麦哥本哈根，2025 年 12 月 6 日- Evaxion A/S（纳斯达克：EVAX）（“Evaxion”），一家专注于开发 AI-Immunology™驱动疫苗的临床阶段科技生物公司，宣布新的数据表明其 AML 疫苗候选者 EVX-04 能够触发强烈的特异性 T 细胞反应，并有效防止临床前模型中的肿瘤生长。</p>
<p>这些数据今天在美国血液学会（ASH）年会和博览会的口头报告中发布，Evaxion 将在会议期间与科学家、医生和潜在商业伙伴讨论这些新发现。</p>
<p>“AML 以高死亡率和巨大的未满足医疗需求为特征，因为当前的治疗选择有限且通常不足。新数据证实了我们对 EVX-04 能够显著改善 AML 患者治疗选择的信念。这是 AI-Immunology™在发现新靶点方面独特能力的又一个例子，使得设计具有变革潜力的疗法成为可能，” Evaxion 的首席科学官 Birgitte Rønø表示。</p>
<p><strong>广泛的肿瘤覆盖</strong></p>
<p>EVX-04 是基于我们的 AI-Immunology™平台开发的，靶向来自黑暗基因组的非传统 ERV 肿瘤抗原。这些抗原在特定肿瘤中选择性表达，但在正常组织中缺失，使其成为极具吸引力的癌症疫苗靶点。</p>
<p>利用 AML 患者的测序数据，AI-Immunology™平台首先识别了 ERV 肿瘤抗原，然后挖掘这些抗原以确定具有免疫识别潜力的小片段。在发现的五百万个 ERV 抗原片段中，AI-Immunology™结合并选择了 16 组最佳的 ERV 片段，基于它们的跨患者相关性和免疫原性潜力。新数据证实，EVX-04 中包含的所有 16 个 ERV 片段均能引发特异性免疫反应，并且 EVX-04 在临床前肿瘤模型中防止肿瘤生长。</p>
<p>数据驱动的靶点选择确保 EVX-04 提供广泛的肿瘤覆盖，无论患者之间的免疫和肿瘤 ERV 抗原差异。因此，EVX-04 被开发为一种现成的疫苗，预制并在诊断后立即可供使用。相同的概念在免疫疗法仍然不足且可以识别保守免疫原性抗原的癌症中具有广泛的适用性。</p>
<p><strong>关于 AML</strong></p>
<p>AML 是一种侵袭性血液恶性肿瘤，其特征是未分化的髓系前体细胞（AML 芽细胞）在骨髓中的克隆扩增。恶性增殖导致正常造血的抑制，导致细胞减少、感染易感性增加、出血和疲劳（Döhner 等，2022）。</p>
<p>AML 是最常见的白血病。它发生在所有年龄组中，但主要是在老年人中观察到，诊断时的中位年龄为 68 岁。</p>
<p>大约 50% 的 AML 患者被认为适合进行强化化疗和干细胞移植。这种组合在年轻患者中的长期总体生存率仅为 40%，在适合的老年患者中则低于 10%。</p>
<p>对于大约 50% 不适合强化治疗的患者，通常是老年人，标准治疗是低强度化疗。然而，缓解期通常较短，报告的 3 年总体生存率仅为 25%（Kantarjian 等，2025）。</p>
<p><strong>关于 ERVs</strong></p>
<p>ERV 是我们基因组中潜伏的古老病毒残余。ERV 在癌症中通常过表达，但在健康组织中则不然，使其对免疫系统可见，因此成为癌症疫苗的有希望靶点。AI-Immunology™在从基因组患者肿瘤数据中识别治疗相关的 ERV 肿瘤抗原方面至关重要。</p>
<p><strong>联系信息</strong></p>
<p>Evaxion A/S</p>
<p>Mads Kronborg</p>
<p>副总裁，投资者关系与沟通</p>
<p>+45 53 54 82 96</p>
<p>mak@evaxion.ai</p>
<p><strong>关于 Evaxion</strong></p>
<p>Evaxion 是一家基于其 AI 平台 AI-Immunology™的开创性科技生物公司。Evaxion 的专有和可扩展 AI 预测模型利用人工智能的力量解码人类免疫系统，并开发针对癌症、细菌疾病和病毒感染的新型免疫疗法。基于 AI-Immunology™，Evaxion 开发了一条临床阶段的肿瘤学管线，包含新型个性化疫苗，以及一条针对具有高未满足医疗需求的细菌和病毒疾病的临床前传染病管线。Evaxion 致力于通过提供创新和靶向的治疗选择来改变患者的生活。有关 Evaxion 及其开创性的 AI-Immunology™平台和疫苗管线的更多信息，请访问我们的网站。</p>
<p><strong>前瞻性声明</strong></p>
<p>本公告包含根据《1933 年证券法》第 27A 条和《1934 年证券交易法》第 21E 条的定义的前瞻性声明。诸如 “目标”、“相信”、“期望”、“希望”、“旨在”、“打算”、“可能”、“或许”、“预期”、“考虑”、“继续”、“估计”、“计划”、“潜在”、“预测”、“项目”、“将”、“可以有”、“可能”、“应该”、“会”、“能够”、“可能” 等词语及其他类似含义的词语和术语标识前瞻性声明。实际结果可能因各种因素而与这些前瞻性声明所指示的结果存在重大差异，包括但不限于与以下风险相关的因素：我们的财务状况和对额外资本的需求；我们的开发工作；我们产品开发活动及临床前和临床试验的成本和成功；利用我们的人工智能平台技术开发的任何获批药品的商业化，包括我们产品候选者的市场接受率和程度；我们对第三方的依赖，包括临床测试和产品制造的进行；我们无法建立合作伙伴关系；政府监管；保护我们的知识产权；员工事务和管理增长；我们的美国存托股票和普通股，国际经济、政治、法律、合规、社会和商业因素的影响，包括通货膨胀，以及其他重大地缘政治和宏观经济事件对我们业务的影响；以及其他影响我们业务运营和财务状况的不确定性。有关这些风险的进一步讨论，请参阅我们最近提交的 20-F 表格年度报告及其他向美国证券交易委员会（SEC）提交的文件，这些文件可在 <strong>www.sec.gov</strong> 获取。除法律要求外，我们不承担更新任何前瞻性声明的义务。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTBNekU1TnlNME1ESXlOemd5TlRBak1qSTFNakE0Tnc9PQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTBNekU1TnlNME1ESXlOemd5TlRBak1qSTFNakE0Tnc9PQ"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/MmVjM2ZjYmItNjE1YS00Y2MwLThlNjQtZDA0ZGMxN2JmZWJmLTEyNjM2NDAtMjAyNS0xMi0wNi1lbg==/tiny/Evaxion.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/MmVjM2ZjYmItNjE1YS00Y2MwLThlNjQtZDA0ZGMxN2JmZWJmLTEyNjM2NDAtMjAyNS0xMi0wNi1lbg==/tiny/Evaxion.png"/></p>

EVAX

<p>Evaxion A/S 在 ASH 年会上展示了其癌症疫苗候选者 EVX-04 的新数据。EVX-04 采用 AI-Immunology™ 开发，针对 ERV 肿瘤抗原，并在治疗急性髓性白血病（AML）方面显示出希望。该疫苗能够诱导强烈的免疫反应，并在临床前模型中防止肿瘤生长。Evaxion 旨在改善 AML 的治疗选择，以应对高死亡率和未满足的医疗需求。该疫苗的现成概念适用于其他难以治疗的癌症</p>

<ul>
<li><strong>Designed with our proprietary AI-Immunology™ platform based on patient sequencing data, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigens</strong></li>
<li><strong>EVX-04 induces targeted immune responses and prevents tumor growth in preclinical models</strong></li>
<li><strong>EVX-04 is an off-the-shelf therapeutic cancer vaccine developed for acute myeloid leukemia (AML), a disease characterized by high mortality rates and massive unmet medical need</strong></li>
<li><strong>The off-the-shelf vaccine concept behind EVX-04 is</strong> <strong>broadly applicable with potential across other hard-to-treat cancers</strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong>基于患者测序数据设计的专有 AI-Immunology™平台，EVX-04 靶向多种非传统内源性逆转录病毒（ERV）肿瘤抗原</strong></li>
<li><strong>EVX-04 在临床前模型中诱导靶向免疫反应并防止肿瘤生长</strong></li>
<li><strong>EVX-04 是一种现成的治疗性癌症疫苗，专为急性髓性白血病（AML）开发，该疾病以高死亡率和巨大的未满足医疗需求为特征</strong></li>
<li><strong>EVX-04 背后的现成疫苗概念</strong> <strong>在其他难治性癌症中具有广泛的潜在应用</strong></li>
</ul>
</div><p>COPENHAGEN, Denmark, December 6, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new data demonstrating that its AML vaccine candidate, EVX-04, triggers strong specific T-cell responses and effectively prevents tumor growth in preclinical models.</p>
<div class="lb-trans"><p>丹麦哥本哈根，2025 年 12 月 6 日- Evaxion A/S（纳斯达克：EVAX）（“Evaxion”），一家专注于开发 AI-Immunology™驱动疫苗的临床阶段科技生物公司，宣布新的数据表明其 AML 疫苗候选者 EVX-04 能够触发强烈的特异性 T 细胞反应，并有效防止临床前模型中的肿瘤生长。</p>
</div><p>The data was presented today in an oral session at the American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida. Evaxion will discuss the new findings with scientists, doctors and potential business partners throughout the meeting.</p>
<div class="lb-trans"><p>这些数据今天在美国血液学会（ASH）年会和博览会的口头报告中发布，Evaxion 将在会议期间与科学家、医生和潜在商业伙伴讨论这些新发现。</p>
</div><p>“AML is characterized by high mortality rates and massive unmet medical need as current treatment options are limited and often insufficient. The new data confirms our belief that EVX-04 could significantly improve treatment options for AML patients. It is another example of the unique capabilities of AI-Immunology™ in finding novel targets enabling the design of therapies with transformative potential,” says Birgitte Rønø, CSO of Evaxion.</p>
<div class="lb-trans"><p>“AML 以高死亡率和巨大的未满足医疗需求为特征，因为当前的治疗选择有限且通常不足。新数据证实了我们对 EVX-04 能够显著改善 AML 患者治疗选择的信念。这是 AI-Immunology™在发现新靶点方面独特能力的又一个例子，使得设计具有变革潜力的疗法成为可能，” Evaxion 的首席科学官 Birgitte Rønø表示。</p>
</div><p><strong>Broad tumor coverage</strong></p>
<div class="lb-trans"><p><strong>广泛的肿瘤覆盖</strong></p>
</div><p>Developed with our AI-Immunology™ platform, EVX-04 targets non-conventional ERV tumor antigens from the dark genome. These antigens are selectively expressed in specific tumors but absent in normal tissue, making them highly attractive cancer vaccine targets.</p>
<div class="lb-trans"><p>EVX-04 是基于我们的 AI-Immunology™平台开发的，靶向来自黑暗基因组的非传统 ERV 肿瘤抗原。这些抗原在特定肿瘤中选择性表达，但在正常组织中缺失，使其成为极具吸引力的癌症疫苗靶点。</p>
</div><p>Using sequencing data from AML patients, the AI-Immunology™ platform first identified ERV tumor antigens and then mined these to determine smaller fragments with the potential for immune recognition. From the five million ERV antigens fragments discovered, AI-Immunology™ combined and selected 16 optimal sets of ERV fragments based on their cross-patient relevance and immunogenic potential. The new data confirms that all 16 ERV fragments included in EVX-04 elicit a specific immune response and that EVX-04 prevents tumor growth in preclinical tumor models.</p>
<div class="lb-trans"><p>利用 AML 患者的测序数据，AI-Immunology™平台首先识别了 ERV 肿瘤抗原，然后挖掘这些抗原以确定具有免疫识别潜力的小片段。在发现的五百万个 ERV 抗原片段中，AI-Immunology™结合并选择了 16 组最佳的 ERV 片段，基于它们的跨患者相关性和免疫原性潜力。新数据证实，EVX-04 中包含的所有 16 个 ERV 片段均能引发特异性免疫反应，并且 EVX-04 在临床前肿瘤模型中防止肿瘤生长。</p>
</div><p>The data-driven target selection ensures that EVX-04 provides broad tumor coverage regardless of immune and tumor ERV antigen differences across patients. Thus, EVX-04 is developed as an off-the-shelf vaccine preproduced and ready for immediate administration after diagnosis. The same concept is broadly applicable across cancers where immunotherapies remain inadequate and conserved immunogenic antigens can be identified.</p>
<div class="lb-trans"><p>数据驱动的靶点选择确保 EVX-04 提供广泛的肿瘤覆盖，无论患者之间的免疫和肿瘤 ERV 抗原差异。因此，EVX-04 被开发为一种现成的疫苗，预制并在诊断后立即可供使用。相同的概念在免疫疗法仍然不足且可以识别保守免疫原性抗原的癌症中具有广泛的适用性。</p>
</div><p><strong>About AML</strong></p>
<div class="lb-trans"><p><strong>关于 AML</strong></p>
</div><p>AML is an aggressive hematologic malignancy characterized by the clonal expansion of undifferentiated myeloid precursor cells (AML blasts) in the bone marrow. The malignant proliferation leads to suppression of normal hematopoiesis, resulting in cytopenia, increased susceptibility to infections, bleeding, and fatigue (Döhner et al. 2022).</p>
<div class="lb-trans"><p>AML 是一种侵袭性血液恶性肿瘤，其特征是未分化的髓系前体细胞（AML 芽细胞）在骨髓中的克隆扩增。恶性增殖导致正常造血的抑制，导致细胞减少、感染易感性增加、出血和疲劳（Döhner 等，2022）。</p>
</div><p>AML is the most frequent leukemia. It occurs across all age groups, however, it is predominantly a disease observed in older adults with a median age at diagnosis of 68 years.</p>
<div class="lb-trans"><p>AML 是最常见的白血病。它发生在所有年龄组中，但主要是在老年人中观察到，诊断时的中位年龄为 68 岁。</p>
</div><p>Approximately 50% of AML patients are considered fit for intensive chemotherapy and stem cell transplantation. This combination is associated with a long-term overall survival rate of only 40% in younger patients and less than 10% in fit older patients.</p>
<div class="lb-trans"><p>大约 50% 的 AML 患者被认为适合进行强化化疗和干细胞移植。这种组合在年轻患者中的长期总体生存率仅为 40%，在适合的老年患者中则低于 10%。</p>
</div><p>For the approximately 50% not fit for intensive treatment, typically the elderly, the standard of care is low-intensity chemotherapy. Remissions are, however, short lived with a 3‐year overall survival rate at only 25% reported (Kantarjian et al. 2025).</p>
<div class="lb-trans"><p>对于大约 50% 不适合强化治疗的患者，通常是老年人，标准治疗是低强度化疗。然而，缓解期通常较短，报告的 3 年总体生存率仅为 25%（Kantarjian 等，2025）。</p>
</div><p><strong>About ERVs</strong></p>
<div class="lb-trans"><p><strong>关于 ERVs</strong></p>
</div><p>ERVs are remnants of ancient viruses lying dormant in our genome. ERVs are often overexpressed in cancer but not in healthy tissue, making them visible to the immune system and hence promising targets for cancer vaccines. AI-Immunology™ is crucial in allowing the identification of therapeutically relevant ERV tumor antigens from genomic patient tumor data.</p>
<div class="lb-trans"><p>ERV 是我们基因组中潜伏的古老病毒残余。ERV 在癌症中通常过表达，但在健康组织中则不然，使其对免疫系统可见，因此成为癌症疫苗的有希望靶点。AI-Immunology™在从基因组患者肿瘤数据中识别治疗相关的 ERV 肿瘤抗原方面至关重要。</p>
</div><p><strong>Contact information</strong></p>
<div class="lb-trans"><p><strong>联系信息</strong></p>
</div><p>Evaxion A/S</p>
<div class="lb-trans"><p>Evaxion A/S</p>
</div><p>Mads Kronborg</p>
<div class="lb-trans"><p>Mads Kronborg</p>
</div><p>Vice President, Investor Relations &amp; Communication</p>
<div class="lb-trans"><p>副总裁，投资者关系与沟通</p>
</div><p>+45 53 54 82 96</p>
<div class="lb-trans"><p>+45 53 54 82 96</p>
</div><p>mak@evaxion.ai</p>
<div class="lb-trans"><p>mak@evaxion.ai</p>
</div><p><strong>About Evaxion</strong></p>
<div class="lb-trans"><p><strong>关于 Evaxion</strong></p>
</div><p>Evaxion is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.</p>
<div class="lb-trans"><p>Evaxion 是一家基于其 AI 平台 AI-Immunology™的开创性科技生物公司。Evaxion 的专有和可扩展 AI 预测模型利用人工智能的力量解码人类免疫系统，并开发针对癌症、细菌疾病和病毒感染的新型免疫疗法。基于 AI-Immunology™，Evaxion 开发了一条临床阶段的肿瘤学管线，包含新型个性化疫苗，以及一条针对具有高未满足医疗需求的细菌和病毒疾病的临床前传染病管线。Evaxion 致力于通过提供创新和靶向的治疗选择来改变患者的生活。有关 Evaxion 及其开创性的 AI-Immunology™平台和疫苗管线的更多信息，请访问我们的网站。</p>
</div><p><strong>Forward-looking statement</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at <strong>www.sec.gov</strong>. We do not assume any obligation to update any forward-looking statements except as required by law.</p>
<div class="lb-trans"><p>本公告包含根据《1933 年证券法》第 27A 条和《1934 年证券交易法》第 21E 条的定义的前瞻性声明。诸如 “目标”、“相信”、“期望”、“希望”、“旨在”、“打算”、“可能”、“或许”、“预期”、“考虑”、“继续”、“估计”、“计划”、“潜在”、“预测”、“项目”、“将”、“可以有”、“可能”、“应该”、“会”、“能够”、“可能” 等词语及其他类似含义的词语和术语标识前瞻性声明。实际结果可能因各种因素而与这些前瞻性声明所指示的结果存在重大差异，包括但不限于与以下风险相关的因素：我们的财务状况和对额外资本的需求；我们的开发工作；我们产品开发活动及临床前和临床试验的成本和成功；利用我们的人工智能平台技术开发的任何获批药品的商业化，包括我们产品候选者的市场接受率和程度；我们对第三方的依赖，包括临床测试和产品制造的进行；我们无法建立合作伙伴关系；政府监管；保护我们的知识产权；员工事务和管理增长；我们的美国存托股票和普通股，国际经济、政治、法律、合规、社会和商业因素的影响，包括通货膨胀，以及其他重大地缘政治和宏观经济事件对我们业务的影响；以及其他影响我们业务运营和财务状况的不确定性。有关这些风险的进一步讨论，请参阅我们最近提交的 20-F 表格年度报告及其他向美国证券交易委员会（SEC）提交的文件，这些文件可在 <strong>www.sec.gov</strong> 获取。除法律要求外，我们不承担更新任何前瞻性声明的义务。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTBNekU1TnlNME1ESXlOemd5TlRBak1qSTFNakE0Tnc9PQ" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE0MzE5NyM0MDIyNzgyNTAjMjI1MjA4Nw=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/MmVjM2ZjYmItNjE1YS00Y2MwLThlNjQtZDA0ZGMxN2JmZWJmLTEyNjM2NDAtMjAyNS0xMi0wNi1lbg==/tiny/Evaxion.png" alt="" original-src="https://ml-eu.globenewswire.com/media/MmVjM2ZjYmItNjE1YS00Y2MwLThlNjQtZDA0ZGMxN2JmZWJmLTEyNjM2NDAtMjAyNS0xMi0wNi1lbg==/tiny/Evaxion.png"/></p>

Evaxion 在 ASH 年会上展示了 EVX-04 的新数据，这是一种用于急性髓性白血病的癌症疫苗候选药物 | EVAX 股票新闻